Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
1 ФГБОУ ВО «Приволжский исследовательский медицинский университет» Минздрава России, Нижний Новгород, Россия; 2 ГБУЗ НО «Городская клиническая больница №5 Нижегородского района города Нижнего Новгорода», Нижний Новгород, Россия tatnecrasova@yandex.ru
Список исп. литературыСкрыть список 1. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации, VII пересмотр. Атеросклероз и дислипидемии. 2020; 1 (38): 7–42. DOI: 10.34687/2219-8202.JAD.2020.01.0002 [Diagnostika i korrektsiia narushenii lipidnogo obmena s tsel'iu profilaktiki i lecheniia ateroskleroza. Rossiiskie rekomendatsii, VII peresmotr. Ateroskleroz i dislipidemii. 2020; 1 (38): 7–42. DOI: 10.34687/2219-8202.JAD.2020.01.0002 (in Russian).] 2. Mach F, Baigent C, Catapano AL et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2019. DOI: 10.1093/eurheartj/ehz455 3. Tuteja S, Rader DJ. SLCO1B1 and Statin Therapy. Circulation: Genom Precision Med 2018; 11: e002320. DOI: 10.1161/CIRCGEN. 118.002320 4. Ежов М.В., Сергиенко И.В., Аронов Д.М и др. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Атеросклероз и дислипидемии. 2017; 3: 5–22. [Ezhov M.V., Sergienko I.V., Aronov D.M et al. Diagnostika i korrektsiia narushenii lipidnogo obmena s tsel'iu profilaktiki i lecheniia ateroskleroza. Ateroskleroz i dislipidemii. 2017; 3: 5–22 (in Russian).] 5. Muntean DM, Thompson PD, Catapano AL et al. Statin-associated myopathy and the quest for biomarkers: can we effectively predict statin-associated muscle symptoms? Drug Discov Today 2017; 22: 85–96. 6. Toth PP, Patti AM, Giglio RV et al; Maciej Banach. Management of Statin Intolerance in 2018: Still More Questions Than Answers. Am J Cardiovasc Drugs 2018; 18 (3): 157–73. DOI: 10.1007/s40256-017-0259-7 7. Chu Ch-Sh, Tseng P-T, Stubbs B et al. Use of statins and the risk of dementia and mild cognitive impairment: A systematic review and meta-analysis. Sci Rep 2018; 8: 5804. DOI: 10.1038/s41598-018-24248-8 8. Turongkaravee S, Jittikoon J, Lukkunaprasit T et al. A systematic review and meta-analysis of genotype-based and individualized data analysis of SLCO1B1 gene and statin-induced myopathy. Pharmacogenomics J 2021. DOI: 10.1038/s41397-021-00208w 9. Bruckert E, Hayem G, Dejager S et al. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients – the PRIMO study. Cardiovasc Drugs Ther 2005; 19: 403–14. 10. Cohen JD, Brinton EA, Ito MK et al. Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users. J Clin Lipidol 2012; 6: 208–15. 11. Adhyaru BB, Jacobson TA. Unblinded ASCOT study results do not rule out that muscle symptoms are an adverse effect of statins. Evid Based Med 2017; 22 (6): 210. DOI: 10.1136/ebmed-2017-110783 12. Кухарчук В.В., Арабидзе Г.Г., Балахонова Т.В. и др. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Евразийская ассоциация кардиологов. Национальное общество по изучению атеросклероза (НОА). М., 2020. [Kukharchuk V.V., Arabidze G.G., Balakhonova T.V. et al. Diagnostika i korrektsiia narushenii lipidnogo obmena s tsel'iu profilaktiki i lecheniia ateroskleroza. Evraziiskaia assotsiatsiia kardiologov. Natsional'noe obshchestvo po izucheniiu ateroskleroza (NOA). Moscow, 2020 (in Russian).] 13. Stroes ES, Thompson PD, Corsini A et al. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J 2015; 36: 1012–22. DOI: 10.1093/eurheartj/ ehv043 14. Commentary SAMS: Statin-Associated Muscle Symptoms – Update 2017. https://www.eas-society.org/page/update_sams_paper 15. Kajinami K, Tsukamoto K, Koba Sh et al. Statin Intolerance Clinical Guide 2018. J Atheroscler Thromb 2020; 27 (4): 375–96. DOI: 10.5551/jat.50948 16. Qari FA. Severe rhabdomyolysis and acute renal failure secondary to use of simvastatin in undiagnosed hypothyroidism. Saudi J Kidney Dis Transpl 2009; 20 (1): 127–9. 17. Ambapkar SN et al. Statin-induced rhabdomyolysis in patient with renal failure and underlying undiagnosed hypothyroidism. Indian J Crit Care Med 2016; 20 (5): 305–7. 18. Луговая Л.А. Клинико-лабораторные признаки поражения мышц у больных компенсированным гипотиреозом на фоне лечения статинами.: дис. … канд. мед. наук. Нижний Новгород, 2018. [Lugovaia L.A. Kliniko-laboratornye priznaki porazheniia myshts u bol'nykh kompensirovannym gipotireozom na fone lecheniia statinami.: dis. … kand. med. nauk. Nizhnii Novgorod, 2018 (in Russian).] 19. Kalliokoski A, Niemi M. Impact of OATP transporters on pharmacokinetics. Br J Pharmacol 2009; 158 (3): 693–705. DOI: 10.1111/j.1476-5381.2009.00430.x 20. SLCO1B1 variants and statin-induced myopathy – a genomewide study. Search Collaborative Group. The N Engl J Med 2008; 359 (8): 789–99. 21. Kitzmiller JP et al. Pharmacogenomics of statins: understanding susceptibility to adverse effects. Pharmaco Personalized Medicine 2016: 9: 97–106. DOI: 10.2147/PGPM.S86013 22. Ramsey LB, Johnson SG, Caudle KE et al. The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update. Clin Pharmacol Ther 2014; 96 (4): 423–8. 23. DeGorter MK, Tirona RG, Schwarz UI et al. Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care. Circ Cardiovasc Genet 2013; 6 (4): 400–4. 24. Ridker PM, Danielson E, Fonseca FAH et al; for the JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359: 2195-207. 25. Rosenson RR, Baker S., Banach et al. Optimizing Cholesterol Treatment in Patient With Muscle Complaints. J Am CollCardiol 2017; 70: 1290–301.